Navigation Links
Northwest Biotherapeutics Conducting Ovarian Cancer Clinical Trial With DCVax(R)-L at University of Pennsylvania
Date:12/27/2007

. These personal cancer biomarkers are then loaded onto the patient's own dendritic cells (the master cells responsible for starting and managing the body's overall immune response), and injected back into the patient through a simple intra-dermal injection, similar to an insulin shot, at various intervals over a period of up to three years.

About Northwest Biotherapeutics

Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products that treat cancers more effectively than current treatments, without toxicity, on a cost-effective basis. The Company has two broad platform technologies: dendritic cell-based vaccines, and therapeutic antibodies. The Company is currently conducting a large clinical trial in Glioblastoma multiforme, which is designed and powered to serve as a pivotal trial. The Company has also received clearance from the FDA for a large Phase III trial in prostate cancer, and clearance from the FDA for Phase I trials in five other cancers. The Company also has a second technology platform, involving monoclonal antibodies to CXCR4, which is at the late pre-clinical development stage.

For further information, please visit the company web site at http://www.nwbio.com.

About the Ovarian Cancer Vaccine Initiative

The Ovarian Cancer Vaccine Initiative (OCVI) is a private philanthropic organization that is funding this NWBT trial at the Hospital of the University of Pennsylvania. Fundraising to underwrite the clinical trial, and translational research that supports it, is actively sought by the OCVI campaign heads and lead donors, Patricia Dunn and Randall Caudill. Donations in cash or stock, which qualify for tax-exemption, may be directed to:

Ovarian Cancer Vaccine Initiative

Account 9078-6137

Schwab Charitable Fund

101 Montgomery Street

San Francisco, CA 94104


SOURCE Northwest Biotherapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
2. First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial
3. Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
4. Clinical Studies of OvaRex in Advanced Ovarian Cancer Fail to Meet Primary Endpoint
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
7. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
8. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
9. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
10. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
11. Novel Technology Breaks Through Cancer Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... Colo. , Nov. 25, 2014   Heska Corporation ... "Heska" or the "Company"), a provider of advanced veterinary ... Robert Grieve , Executive Chair, will attend The Benchmark ... 2014. The one-on-one conference will be held at The Palmer ... from 8 a.m. to 2:30 p.m. Please email ...
(Date:11/26/2014)... , Nov. 25, 2014  Array ... today announced that its Chief Executive Officer, ... the following upcoming conferences.  The public is ... webcasts on the Array BioPharma website:  ... 3, 2014Time:1:30 p.m.  Eastern Time Location: Palace ...
(Date:11/26/2014)... LONDON , Nov. 25, 2014 ... AZN ) today announced that AMAGINE-2 TM , a ... in more than 1,800 patients with moderate-to-severe plaque psoriasis, met ... (ustekinumab) and placebo at week 12. Brodalumab 210 mg given ... each shown to be superior to Stelara on the primary ...
Breaking Medicine Technology:Heska to Attend Benchmark Micro Cap Discovery Conference 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 3Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 5Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 6Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 7Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 8Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 9Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 10
... SEOUL, South Korea, Dec. 5, 2011 /PRNewswire-Asia/ -- The ... Industry Development Institute announced that the Health Authority-Abu Dhabi ... National University Hospital, Asian Medical Center and Seoul St. ... a patient treatment-reference system in Abu Dhabi, on Nov. ...
... BEIJING, Dec. 5, 2011 /PRNewswire-Asia/ -- GC-Rise Pharmaceutical Co. ... holds a majority stake, was recently listed as one ... companies which rides on high growth over the past ... women,s health in China, saw its operating revenues rising ...
Cached Medicine Technology:South Korea Signs Accord with Abu Dhabi Health Authority on Hospital Service Agreement 2Women Health Expert GC-Rise Listed in Deloitte's 50 Top-performing Companies 2
(Date:11/27/2014)... By Randy Dotinga ... -- Some people,s brains seem pre-wired to acquire a second ... beyond their mother tongue will likely gain a brain boost, ... connected and integrated after learning," said study co-author Ping Li, ... Pennsylvania State University. But it,s even more interesting, Li said, ...
(Date:11/27/2014)... November 27, 2014 In order to enable ... Sharpes, Fla., designed an easy way to avoid touching a ... He then created a prototype of the patent-pending Toilet Tamer, ... a toilet seat and/or lid in a more sanitary manner. ... spread of germs. Overall, it promotes good hygiene and peace ...
(Date:11/27/2014)... November 27, 2014 Tylenol lawsuits ( ... allegedly injured by the medication are continuing to move ... is looking ahead to a status conference in December, ... Scheduling Order issued earlier this year, a conference in ... at 10:00 a.m. Items likely to be discussed at ...
(Date:11/27/2014)... “LAB.C” was featured on NewsWatch as part ... coolest technology products available to consumers. Mallory Sofastaii, a technology ... and shared with viewers the company offers a cable ... , Consumers love portability and functionality. A unique mobile ... the iPhone5 and 5S has a portable USB charger built ...
(Date:11/27/2014)... (PRWEB) November 27, 2014 HealthPostures, ... office ergonomics equipment , has announced that it ... Commercial Office Environments. The partnership will put HealthPostures' ... furnishings location. , In addition to having its ... dealer partnership promotes HealthPostures' products with the business ...
Breaking Medicine News(10 mins):Health News:Some People May Be Pre-Wired to Be Bilingual 2Health News:Some People May Be Pre-Wired to Be Bilingual 3Health News:Federal Litigation Presiding over Tylenol Lawsuits Looks Ahead to Status Conference in December, Bernstein Liebhard LLP Reports 2Health News:Federal Litigation Presiding over Tylenol Lawsuits Looks Ahead to Status Conference in December, Bernstein Liebhard LLP Reports 3Health News:Top Mobile Friendly Accessories were Featured on NewsWatch Television on October 30, 2014 2Health News:Ergonomics Manufacturer Announces New Partnership with Office Supply Dealer 2
... the number of seats in existing facilities to fill the ... the central government's proposed quota policy, says Chief Minister Arjun ... medical institutions and open more institutes in the state," said ... doctors and this was the only to "adjust the numbers". ...
... mosquito-transmitted viral fever, has claimed 12 lives in Betul district ... more districts//. ,'With three more deaths Sunday - two ... number of deaths allegedly due to Chikangunya fever in Betul ... here said Thursday. ,'The dead include a 10-year-old ...
... peripheral artery disease (PAD) patients have showed lesser death ... ,Researchers have also indicated that less physically active ... ,‘We found that there is a survival ... active in their daily routines,’ said Mary M. McDermott, ...
... can cause developmental delays in infants whose mothers were ... banned in the United States, officials in Africa plan ... malaria. ,According to study author Brenda Eskenazi, a ... the University of California, Berkeley, the potential benefits of ...
... that vaccines that contain mercury do not increase ... scientists examined patterns between the developmental disorder and ... in the journal Pediatrics. ,Their research ... children given shots after thimerosal, a mercury-based preservative, ...
... the All India Institute of Medical Sciences remained crippled ... to protest the move to sack its Director P ... were closed since last evening as resident doctors and ... apex body headed by Union Health Minister A Ramadoss ...
Cached Medicine News:Health News:Chikungunya Death Toll Raises to 12 in Madhya Pradesh 2Health News:Physical Activity benefited Peripheral Artery Disease (PAD) patients 2Health News:Developmental Delays in Infants Linked to DDT 2
... This stool is unquestionably the finest operating ... especially for the ophthalmic surgeon who must ... A poor stool can unexpectedly shift resulting in ... solid base of five sturdy casters. A "foot ...
This is a 2.5x focusing Galilean telescope with a range from 70cm to infinity. Ideal for use at sporting events, as well as for a wide range of hobbies....
This 6x or 8x aspheric magnifier is fitted with a distance piece and is particularly useful for patients with tremor or focusing difficulties. The magnifier can be either spectacle mounted or hand h...
All Keeler magnifiers and telescope are available on a clip to fit over the patient's own spectacle...
Medicine Products: